{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:59:05Z","timestamp":1785369545833,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:28:33Z","timestamp":1779449313000},"page":"573-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Horizon Ahead"],"prefix":"10.1016","volume":"55","author":[{"given":"Vala","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy H.","family":"Pettus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10146","key":"10.1016\/j.ecl.2026.04.012_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.012_bib2","doi-asserted-by":"crossref","first-page":"e1001321","DOI":"10.1371\/journal.pmed.1001321","article-title":"Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: scottish registry linkage study","volume":"9","author":"Livingstone","year":"2012","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.012_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.012_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.ecl.2026.04.012_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.012_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.012_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.012_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2337\/dc25-2379","article-title":"Tirzepatide in adults with type 1 diabetes: a phase 2 randomized placebo-controlled clinical trial","volume":"49","author":"Snaith","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2026.04.012_bib9","unstructured":"ClinicalTrials.gov. SURPASS-T1D-2. NCT06962280."},{"key":"10.1016\/j.ecl.2026.04.012_bib10","unstructured":"ClinicalTrials.gov. Study of CT-868 in type 1 diabetes. NCT06062069."},{"key":"10.1016\/j.ecl.2026.04.012_bib11","doi-asserted-by":"crossref","unstructured":"FDA. Symlin (pramlintide acetate) approval history. 2005.","DOI":"10.3833\/pdr.v2005i60.663"},{"issue":"04","key":"10.1016\/j.ecl.2026.04.012_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2005-837662","article-title":"Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets","volume":"113","author":"Ratner","year":"2005","journal-title":"Experimental and clinical endocrinology & diabetes"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.012_bib13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1742-1241.2006.01187.x","article-title":"Pramlintide in the treatment of diabetes","volume":"60","author":"Edelman","year":"2006","journal-title":"International journal of clinical practice"},{"issue":"22","key":"10.1016\/j.ecl.2026.04.012_bib14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New england journal of medicine"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.012_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ecl.2026.04.012_bib16","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.012_bib17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium\u2013glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes care"},{"key":"10.1016\/j.ecl.2026.04.012_bib18","unstructured":"ClinicalTrials.gov. Continuous ketone monitoring with SGLT inhibitors. NCT07211802."},{"key":"10.1016\/j.ecl.2026.04.012_bib19","unstructured":"National Institutes of Health. Ketone monitoring and DKA prevention initiatives."},{"issue":"8","key":"10.1016\/j.ecl.2026.04.012_bib20","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.1424934112","article-title":"Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.012_bib21","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s41591-022-02011-x","article-title":"Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial","volume":"28","author":"Pettus","year":"2022","journal-title":"Nature medicine"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.012_bib22","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/dom.13202","article-title":"Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial","volume":"20","author":"Pettus","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.012_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"Chui","year":"2024","journal-title":"Trends in Endocrinology & Metabolism"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.012_bib24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.7150\/ijbs.25026","article-title":"The role of FGF21 in type 1 diabetes and its complications","volume":"14","author":"Zhang","year":"2018","journal-title":"International journal of biological sciences"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:24:29Z","timestamp":1785367469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000332"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.012","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Horizon Ahead","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}